Een geneesmiddel wat al tientallen jaren wordt gemaakt willen we registreren. Welke onderzoeken moeten we nog uitvoeren, welke onderzoeken zijn overbodig als het al zolang klinisch wordt gebruikt. En wat kunnen we hieruit leren voor apotheekbereidingen in het algemeen en voor apotheekbereidingen die we beter willen beschermen door ze te registreren?
Hospital expenditure of expensive drugs increases yearly. In addition, shortages are becoming more common. To assure access to healthcare and treatment in the future, sustainable use of expensive drugs is very important. This research aims to optimize treatment with regard to efficacy and safety, while aiming to reduce drug costs.
The research focusses on several aspects related to reimbursement: factors influencing the time to reimbursement, measures to improve the time to reimbursement, differences in the clinical evidentiary requirements of oncology assessment, EMA versus HTA bodies and changes in economic evaluations of oncology drugs in time.
The research project aims to develop models for the prediction of disease duration in order to support personalized and cost-effective care of depression patients. Using these models, optimal treatment strategies will be analyzed. In this project, we also want to predict treatment resistant depression as a specific subgroup and conduct cost-effectiveness analyses of different psychotherapy strategies and quantify the impact of structural uncertainty and parameter uncertainty on the results of cost-effectiveness evaluations.